For: | Ampuero J, Romero-Gomez M. Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin. World J Hepatol 2015; 7(8): 1105-1111 [PMID: 26052399 DOI: 10.4254/wjh.v7.i8.1105] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v7/i8/1105.htm |
Number | Citing Articles |
1 |
Nan Cai, Shu-Juan Xie, Dong-Bo Qiu, Chang-Chang Jia, Cong Du, Wei Liu, Jia-Jie Chen, Qi Zhang. Potential effects of α-mangostin in the prevention and treatment of hepatocellular carcinoma. Journal of Functional Foods 2016; 26: 309 doi: 10.1016/j.jff.2016.08.014
|
2 |
Svenja Nölting, Julian Maurer, Gerald Spöttl, Elke Tatjana Aristizabal Prada, Clemens Reuther, Karen Young, Márta Korbonits, Burkhard Göke, Ashley Grossman, Christoph J. Auernhammer, Olorunseun Ogunwobi. Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways. PLOS ONE 2015; 10(12): e0143830 doi: 10.1371/journal.pone.0143830
|
3 |
Wenjing Xiong, Liru Li, Xue Hui, Yue Liu, Hongbin Li, Yue Zhang, Shu Zhao. The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma. Clinical and Translational Oncology 2024; 26(9): 2240 doi: 10.1007/s12094-024-03438-z
|
4 |
Wenhua Li, Bin Zhao, Qianwen Wang, Junxia Lu, Xiangwei Wu, Xueling Chen. M2 macrophage exosomes promote resistance to sorafenib in hepatocellular carcinoma cells via miR-200c-3p. International Immunopharmacology 2024; 139: 112807 doi: 10.1016/j.intimp.2024.112807
|
5 |
Liang Gu, Sourav Taru Saha, Jodie Thomas, Mandeep Kaur. Targeting cellular cholesterol for anticancer therapy. The FEBS Journal 2019; 286(21): 4192 doi: 10.1111/febs.15018
|
6 |
Jelena Todoric, Laura Antonucci, Michael Karin. Targeting Inflammation in Cancer Prevention and Therapy. Cancer Prevention Research 2016; 9(12): 895 doi: 10.1158/1940-6207.CAPR-16-0209
|
7 |
R. N. Mustafin. Possibilities of using statins in comprehensive antitumor treatment. MD-Onco 2022; 2(3): 59 doi: 10.17650/2782-3202-2022-2-3-59-64
|
8 |
Pedro E. Lázaro-Mixteco, José M. González-Coronel, Laura Hernández-Padilla, Lorena Martínez-Alcantar, Enrique Martínez-Carranza, Jesús Salvador López-Bucio, Ángel A. Guevara-García, Jesús Campos-García. Transcriptomics Reveals the Mevalonate and Cholesterol Pathways Blocking as Part of the Bacterial Cyclodipeptides Cytotoxic Effects in HeLa Cells of Human Cervix Adenocarcinoma. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.790537
|
9 |
Emanuele Rinninella, Lucia Cerrito, Irene Spinelli, Marco Cintoni, Maria Cristina Mele, Maurizio Pompili, Antonio Gasbarrini. Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. Journal of Clinical and Translational Hepatology 2017; (XX): 1 doi: 10.14218/JCTH.2017.00002
|
10 |
R. N. Mustafin. Prospects for the use of statins in the treatment of neurofibromatosis type 1. Advances in Molecular Oncology 2022; 9(3): 15 doi: 10.17650/2313-805X-2022-9-3-15-23
|
11 |
Samir Agrawal, Padman Vamadevan, Ndaba Mazibuko, Robin Bannister, Raphael Swery, Shanna Wilson, Sarah Edwards. A New Method for Ethical and Efficient Evidence Generation for Off-Label Medication Use in Oncology (A Case Study in Glioblastoma). Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00681
|
12 |
José A. del Campo, Marta García-Valdecasas, Antonio Gil-Gómez, Ángela Rojas, Paloma Gallego, Javier Ampuero, Rocío Gallego-Durán, Helena Pastor, Lourdes Grande, Francisco J. Padillo, Jordi Muntané, Manuel Romero-Gómez, Matias A Avila. Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy. PLOS ONE 2018; 13(1): e0191805 doi: 10.1371/journal.pone.0191805
|
13 |
Fatemeh Sadat Hosseini, Abdolreza Ahmadi, Prashant Kesharwani, Hossein Hosseini, Amirhossein Sahebkar. Regulatory effects of statins on Akt signaling for prevention of cancers. Cellular Signalling 2024; 120: 111213 doi: 10.1016/j.cellsig.2024.111213
|
14 |
Allison J. Kasmari, Amy Welch, Guodong Liu, Doug Leslie, Thomas McGarrity, Thomas Riley. Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. The American Journal of Medicine 2017; 130(6): 746.e1 doi: 10.1016/j.amjmed.2016.12.029
|
15 |
Shu-Xiang Cui, Wen-Na Shi, Zhi-Yu Song, Shu-Qing Wang, Xin-Feng Yu, Zu-Hua Gao, Xian-Jun Qu. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. Oncotarget 2016; 7(24): 36767 doi: 10.18632/oncotarget.9168
|
16 |
Alexander Kusnik, Nicole Hunter, Erik Rasbach, Thomas Miethke, Christoph Reissfelder, Matthias Philip Ebert, Andreas Teufel. Co-Medication and Nutrition in Hepatocellular Carcinoma: Potentially Preventative Strategies in Hepatocellular Carcinoma. Digestive Diseases 2021; 39(5): 526 doi: 10.1159/000514277
|
17 |
Rebecca Baqiyyah N. Conway, Staci Sudenga, Donald McClain, William J. Blot. Diabetes and liver cancer risk: A stronger effect in Whites than Blacks?. Journal of Diabetes and its Complications 2021; 35(3): 107816 doi: 10.1016/j.jdiacomp.2020.107816
|
18 |
Ulfa Kholili, Alvin Hartanto Kurniawan, Choirina Winda, Ummi Maimunah, Poernomo Budi Setiawan. The Role of Metformin as Chemopreventive Strategies for Hepatocellular Carcinoma. Research Journal of Pharmacy and Technology 2023; : 377 doi: 10.52711/0974-360X.2023.00065
|
19 |
Hyun-seok Kim, Hashem B. El-Serag. The Epidemiology of Hepatocellular Carcinoma in the USA. Current Gastroenterology Reports 2019; 21(4) doi: 10.1007/s11894-019-0681-x
|
20 |
Teodor T. Postolache, Deborah R. Medoff, Clayton H. Brown, Li Juan Fang, Sanjaya K. Upadhyaya, Christopher A. Lowry, Michael Miller, Julie A. Kreyenbuhl. Lipophilic vs. hydrophilic statins and psychiatric hospitalizations and emergency room visits in US Veterans with schizophrenia and bipolar disorder. Pteridines 2021; 32(1): 48 doi: 10.1515/pteridines-2020-0028
|
21 |
Undurti N. Das. Bioactive Lipids as Mediators of the Beneficial Actions of Statins. Journal of Cardiovascular Pharmacology 2019; 74(1): 4 doi: 10.1097/FJC.0000000000000689
|
22 |
Yuri Cho, Eun Ju Cho, Jeong-Ju Yoo, Young Chang, Goh Eun Chung, In Young Choi, Sang-Hyun Park, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu. The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.863352
|
23 |
Ibrahim El Sayed, Maged W. Helmy, Hanan S. El-Abhar. Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma. Life Sciences 2018; 213: 248 doi: 10.1016/j.lfs.2018.10.002
|
24 |
Sung-Wan Kim, Hee-Ju Kang, Min Jhon, Ju-Wan Kim, Ju-Yeon Lee, Adam J. Walker, Bruno Agustini, Jae-Min Kim, Michael Berk. Statins and Inflammation: New Therapeutic Opportunities in Psychiatry. Frontiers in Psychiatry 2019; 10 doi: 10.3389/fpsyt.2019.00103
|
25 |
Shujuan Ma, Yixiang Zheng, Yanni Xiao, Pengcheng Zhou, Hongzhuan Tan. Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine 2017; 96(19): e6888 doi: 10.1097/MD.0000000000006888
|
26 |
Silviu Marcel Stanciu, Mariana Jinga, Daniela Miricescu, Constantin Stefani, Remus Iulian Nica, Iulia-Ioana Stanescu-Spinu, Ileana Adela Vacaroiu, Maria Greabu, Silvia Nica. mTOR Dysregulation, Insulin Resistance, and Hypertension. Biomedicines 2024; 12(8): 1802 doi: 10.3390/biomedicines12081802
|
27 |
Ángela Rojas, María Rosario García-Lozano, Antonio Gil-Gómez, Manuel Romero-Gómez, Javier Ampuero. Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies. Journal of Clinical and Translational Hepatology 2022; 10(2): 356 doi: 10.14218/JCTH.2021.00247
|
28 |
Harvey J. Murff, Christianne L. Roumie, Robert A. Greevy, Amber J. Hackstadt, Lucy E. D’Agostino McGowan, Adriana M. Hung, Carlos G. Grijalva, Marie R. Griffin. Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer. Cancer Causes & Control 2018; 29(9): 823 doi: 10.1007/s10552-018-1058-4
|